Sanofi | SNY - Current Assets


Sanofi reported EUR30.16B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
AbbVie USD 33.53B 4.47B Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
AstraZeneca USD 29.61B 890M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Canopy Growth CAD 529.47M 4.8M Mar/2026
Corcept Therapeutics USD 426.03M 59.43M Mar/2026
Drreddys Laboratories INR 301.98B 298.66B Mar/2026
Eli Lilly USD 54.84B 794M Mar/2026
Genmab DKK 2.88B 1.59B Dec/2025
GlaxoSmithKline GBP 17.76B 251M Mar/2026
Glaxosmithkline GBP 17.76B 5.83B Mar/2026
J&J USD 59.17B 3.55B Mar/2026
Lakefront Biotherapeutics EUR 3.06B 18.72M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Pacira USD 514.96M 33.01M Mar/2026
Perrigo USD 2.71B 85M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Phibro Animal Health USD 894.07M 31.88M Mar/2026
Prestige Brands USD 431.48M 1.94M Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025
Sanofi EUR 30.16B 789M Mar/2026
Sanofi EUR 30.16B 789M Mar/2026
Supernus Pharmaceuticals USD 731.58M 87.4M Mar/2026
UCB EUR 6.05B 733M Dec/2025
Zoetis USD 6.47B 294M Mar/2026